EGFR and neoplasm: In addition, co-treatment with seribantumab and EGFR-neutralizing antibodies in EGFR mutant-bearing lung cancer cell lines and xenograft models, which became resistant to EGFR inhibitor/neutralizing antibodies, was able to overcome resistance to EGFR-targeted therapy and inhibit tumor growth [6].